Add to ORKGThe recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has been lauded as a success story for personalized cancer therapy since short-term clinical responses were observed in the majority of patients. However, initial responses were followed by subsequent tumor re-growth, and a subset of patients showed intrinsic resistance. Bi-directional translational efforts are now essential to determine the mechanisms underlying acquired/secondary and intrinsic resistance to RAF inhibitors
Abstract Treatment of BRAF‐mutant melanomas with MAP kinase pathway inhibitors is paradigmatic of th...
Purpose: To examine mechanisms that determine long-term responses of B-RAF<sup>V600E</sup> melanoma ...
SummaryBRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually r...
The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has ...
The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has ...
Melanoma cells driven by mutant v-raf murine sarcoma viral oncogene homolog B1 (B-RAF) are highly re...
The discovery of activating mutations in BRAF at high frequency in cutaneous melanoma opened the doo...
The identification of BRAF V600E as a driving mutation in approximately 50% of melanoma and the subs...
In early 2011, we reviewed the initial success of the RAF inhibitor vemurafenib in mutant V600 BRAF ...
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mut...
Background The introduction of targeted therapies for the treatment of BRAF-mutant melanomas have im...
RAF inhibitors have the unique property of transactivating RAS-dependent RAF dimers in most cells bu...
La prise en charge du mélanome métastatique a été bouleversée par les thérapies ciblées comme les in...
BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse ...
This systematic review investigated the literature on acquired v-raf murine sarcoma viral oncogene h...
Abstract Treatment of BRAF‐mutant melanomas with MAP kinase pathway inhibitors is paradigmatic of th...
Purpose: To examine mechanisms that determine long-term responses of B-RAF<sup>V600E</sup> melanoma ...
SummaryBRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually r...
The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has ...
The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has ...
Melanoma cells driven by mutant v-raf murine sarcoma viral oncogene homolog B1 (B-RAF) are highly re...
The discovery of activating mutations in BRAF at high frequency in cutaneous melanoma opened the doo...
The identification of BRAF V600E as a driving mutation in approximately 50% of melanoma and the subs...
In early 2011, we reviewed the initial success of the RAF inhibitor vemurafenib in mutant V600 BRAF ...
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mut...
Background The introduction of targeted therapies for the treatment of BRAF-mutant melanomas have im...
RAF inhibitors have the unique property of transactivating RAS-dependent RAF dimers in most cells bu...
La prise en charge du mélanome métastatique a été bouleversée par les thérapies ciblées comme les in...
BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse ...
This systematic review investigated the literature on acquired v-raf murine sarcoma viral oncogene h...
Abstract Treatment of BRAF‐mutant melanomas with MAP kinase pathway inhibitors is paradigmatic of th...
Purpose: To examine mechanisms that determine long-term responses of B-RAF<sup>V600E</sup> melanoma ...
SummaryBRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually r...